Background A number of studies assessed the association of ？675 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor (PAI)-1 gene with asthma in different populations. However, most studies reported inconclusive results. A meta-analysis was conducted to investigate the association between polymorphism in the PAI-1 gene and asthma susceptibility. Methods Databases including Pubmed, EMBASE, HuGE Literature Finder, Wanfang Database, China National Knowledge Infrastructure (CNKI) and Weipu Database were searched to find relevant studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association in the dominant model, recessive model, codominant model, and additive model. Results Eight studies involving 1817 cases and 2327 controls were included. Overall, significant association between 4G/5G polymorphism and asthma susceptibility was observed for 4G4G+4G5G vs. 5G5G (OR = 1.56, 95% CI 1.12–2.18, P = 0.008), 4G/4G vs. 4G/5G+5G/5G (OR = 1.38, 95% CI 1.06–1.80, P = 0.02), 4G/4G vs. 5G/5G (OR = 1.80, 95% CI 1.17–2.76, P = 0.007), 4G/5G vs. 5G/5G (OR = 1.40, 95% CI 1.07–1.84, P = 0.02), and 4G vs. 5G (OR = 1.35, 95% CI 1.08–1.68, P = 0.008). Conclusions This meta-analysis suggested that the ？675 4G/5G polymorphism of PAI-1 gene was a risk factor of asthma.
References
[1]
Masoli M, Fabian D, Holt S, Beasley R (2004) The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59: 469–478.
[2]
Mukherjee AB, Zhang Z (2011) Allergic Asthma: Influence of Genetic and Environmental Factors. J Biol Chem 286: 32883–32889.
[3]
Kelly MM, Leigh R, Bonniaud P, Ellis R, Wattie J, et al. (2005) Epithelial expression of profibrotic mediators in a model of allergen-induced airway remodeling. Am J Respir Cell Mol Biol 32: 99–107.
[4]
Kowal K, Bodzenta-Lukaszyk A, Pampuch A, Szmitkowski M, Donati MB, et al. (2007) Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge. Int Arch Allergy Imm 144: 240–246.
[5]
Xu J, Postma DS, Howard TD, Koppelman GH, Zheng SL, et al. (2000) Major genes regulating total serum immunoglobulin E levels in families with asthma. Am J Hum Genet 67: 1163–1173.
[6]
Eriksson P, Kallin B, Van't Hooft FM, B？venholm P, Hamsten A (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. P Natl Acad Sci USA 92: 1851–1855.
[7]
Bu？ková D, Izakovi？ová Hollá L, Vácha J (2002) Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy 57: 446–448.
[8]
Pampuch A, Kowal K, Bodzenta-Lukaszyk A, Castelnuovo AD, Chyczewski L, et al. (2006) The ？675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients. Allergy 61: 234–238.
[9]
Hizawa N, Maeda Y, Konno S, Fukui Y, Takahashi D, et al. (2006) Genetic polymorphisms at FCεR1B and PAI-1 and asthma susceptibility. Clin Exp Allergy 2006 36: 872–876.
[10]
Kowal K, Bodzenta-Lukaszyk A, Pampuch A, Szmitkowski M, Zukowski S, et al. (2008) Analysis of ？675 4G/5G SERPINE1 and C-159T CD14 polymorphisms in house dust mite-allergic asthma patients. J Investig Allergol Clin Immunol 18: 284–292.
[11]
Ozbek OY, Atac FB, Ogus E, Ozbek N (2009) Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in Turkish children with asthma and allergic rhinitis. Allergy Asthma Proc 30: 41–46.
[12]
Cosan D, Kurt E, Kurt H, Degirmenci I, Ku？ukarabaci B, et al. (2009) Plasminogen Activator Inhibitor Type-1 Gene 4G/5G Polymorphism in Turkish Adult Patients with Asthma. Genet Test Mol Biomarkers 13: 543–546.
[13]
Zhang X, Ling J, Liu C, Su N, Cheng X, et al. (2009) A study of genetic polymorphism at PAI-1 and asthma susceptibility. Zhonghua Jie He He Hu Xi Za Zhi 32: 210–212.
[14]
Dijkstra A, Postma DS, Bruinenberg M, van Diemen CC, Boezen H, Koppelman G, et al. (2011) SERPINE1 ？675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response. Eur Respir J 38: 1036–1043.
[15]
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101.
[16]
Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
[17]
Koppelman GH (2006) Gene by environment interaction in asthma. Curr Allergy Asthma Rep 6: 103–111.
[18]
Murphy DM, O'Byrne PM (2010) Recent advances in the pathophysiology of asthma. Chest 137: 1417–1426.
[19]
Ma Z, Paek D, Oh C (2009) Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation. Clin Exp Allergy 39: 1136–1144.
[20]
Savov JD, Brass DM, Berman KG, McElvania E, Schwartz DA (2003) Fibrinolysis in LPS-induced chronic airway disease. Am J Physiol Lung Cell Mol Physiol 285: L940–L948.
[21]
Sejima T, Madoiwa S, Mimuro J, Sugo T, Okada K, et al. (2005) Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immun 174: 8135–8143.
[22]
Oh CK, Ariue B, Alban RF, Shaw B, Cho SH (2002) PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 294: 1155–1160.
[23]
Festa A, D'Agostino R Jr, Rich SS, Jenny NS, Tracy RP, et al. (2003) Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 107: 2422–2427.
[24]
Cho SH, Hall IP, Wheatley A, Dewar J, Abraha D, et al. (2001) Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J Allergy Clin Immun 108: 212–214.
[25]
Salanti G, Sanderson S, Higgins J (2005) Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7: 13–20.
